title: Emerging therapeutics for the treatment of diabetic nephropathy.
abstract: Diabetic nephropathy (DN) is the most common pathology contributing to the development of chronic kidney disease (CKD). DN caused by hypertension and unmitigated inflammation in diabetics, renders the kidneys unable to perform normally, and leads to renal fibrosis and organ failure. The increasing global prevalence of DN has been directly attributed to rising incidences of Type II diabetes, and is now the largest non-communicable cause of death worldwide. Despite the high morbidity, successful new treatments for DN are lacking. This review seeks to provide new insight on emerging clinical candidates under investigation for the treatment of DN.
authors: Small Molecule Discovery Research, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA. Electronic address: jehrod.brenneman@boehringer-ingelheim.com.
authors: Jehrod
authors: J
authors: Brenneman
authors: Research Networking, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA.
authors: Jon
authors: J
authors: Hill
authors: Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877, USA.
authors: Steve
authors: S
authors: Pullen
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy*; D006801:Humans
keywords: Diabetic nephropathy; Fibrosis; Inflammation; Kidney disease; Therapeutics